Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- 17 Jun 2017 Results (n=123) assessing efficacy and safety presented at the 18th Annual Congress of the European League Against Rheumatism.
- 16 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 16 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.